Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Clodi, M; Abrahamian, H; Brath, H; Schernthaner, G; Brix, J; Ludvik, B; Drexel, H; Saely, CH; Fasching, P; Rega-Kaun, G; Föger, B; Francesconi, C; Fröhlich-Reiterer, E; Kautzky-Willer, A; Harreiter, J; Luger, A; Resl, M; Riedl, M; Winhofer, Y; Hofer, SE; Hoppichler, F; Huber, J; Kaser, S; Ress, C; Lechleitner, M; Aberer, F; Mader, JK; Sourij, H; Toplak, H; Paulweber, B; Stechemesser, L; Pieber, T; Prager, R; Stingl, H; Stulnig, T; Rami-Merhar, B; Drexel, H; Roden, M; Schelkshorn, C; Wascher, TC; Weitgasser, R; Zlamal-Fortunat, S.
[Antihyperglycemic treatment guidelines for diabetes mellitus type 2 (Update 2023)].
Wien Klin Wochenschr. 2023; 135(Suppl 1): 32-44.
Doi: 10.1007/s00508-023-02186-4
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Aberer Felix
- Fröhlich-Reiterer Elke
- Mader Julia
- Pieber Thomas
- Sourij Harald
- Toplak Hermann
- Wascher Thomas
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Hyperglycemia significantly contributes to complications in patients with diabetes mellitus. While lifestyle interventions remain cornerstones of disease prevention and treatment, most patients with type 2 diabetes will eventually require pharmacotherapy for glycemic control. The definition of individual targets regarding optimal therapeutic efficacy and safety as well as cardiovascular effects is of great importance. In this guideline we present the most current evidence-based best clinical practice data for healthcare professionals.
- Find related publications in this database (Keywords)
- Diabetes mellitus Type 2
- Therapy Glucose lowering